Comparative Pharmacology
Head-to-head clinical analysis: CONEXXENCE versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONEXXENCE versus PORTIA 21.
CONEXXENCE vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive